Get the Stockscreener App
14.28
0.03%
-0.0063
Amicus Therapeutics Inc stock is traded at $14.28, with a volume of 3.38M.
It is down -0.03% in the last 24 hours and up +0.25% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$14.29
Open:
$14.29
24h Volume:
3.38M
Relative Volume:
0.34
Market Cap:
$4.48B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-116.60
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
-0.17%
1M Performance:
+0.25%
6M Performance:
+135.73%
1Y Performance:
+47.57%
1-Day Range:
$14.28
$14.29
1-Week Range:
$14.27
$14.36
52-Week Range:
$5.51
$14.38
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.29 | 4.48B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.50 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
878.10 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
364.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.03 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-29-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Market Recap: What is the long term forecast for Amicus Therapeutics Inc stockMarket Growth Report & Weekly High Momentum Picks - baoquankhu1.vn
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders - marketscreener.com
Amicus Therapeutics CEO Campbell sells $1.07 million in shares By Investing.com - Investing.com Canada
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Sells 75,000 Shares - TradingView
How the $4.8B Amicus deal with BioMarin came together - The Business Journals
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Amicus Therapeutics (FOLD): Jefferies Downgrades to Hold, Lowers Price Target | FOLD Stock News - GuruFocus
Jefferies downgrades Amicus Therapeutics stock to Hold on acquisition outlook - Investing.com Canada
How A New Price Target Is Shaping The Amicus Therapeutics (FOLD) Investment Story - Yahoo Finance
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease - Yahoo Finance
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - TradingView
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Amicus Therapeutics, Inc. $FOLD Holdings Boosted by Stephens Investment Management Group LLC - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - FinancialContent
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Yahoo Finance
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com - Investing.com Nigeria
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighHere's What Happened - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.36 USD - Investing.com
Aug Shorts: Is Amicus Therapeutics Inc. showing insider buyingWeekly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: 19.5% Revenue Growth and Potential Upside Attract Investors - DirectorsTalk Interviews
MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Finviz
BioMarin Expands Rare Disease Portfolio With $4.8 Billion Amicus Acquisition - The Healthcare Technology Report.
BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN
Amicus Therapeutics : Legend (1) - marketscreener.com
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum - Yahoo Finance
Peregrine Capital Management LLC Acquires 72,178 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Why Amicus Therapeutics Inc. stock remains undervalued - Улправда
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential - Yahoo Finance
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Will Amicus Therapeutics Inc. stock benefit from sector rotationPortfolio Value Report & Entry Point Strategy Guides - ulpravda.ru
How Amicus Therapeutics Inc. stock performs in rising dollar environment2025 Key Highlights & Weekly High Momentum Picks - ulpravda.ru
Risk Off: Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Why retail investors pile into Amicus Therapeutics Inc. stockWatch List & Technical Buy Zone Confirmations - ulpravda.ru
Buyback Watch: Will Amicus Therapeutics Inc. stock remain a Wall Street favoriteWeekly Gains Summary & Risk Controlled Stock Alerts - ulpravda.ru
How Amicus Therapeutics Inc. stock compares to industry benchmarksSell Signal & Low Drawdown Investment Strategies - ulpravda.ru
Can Amicus Therapeutics Inc. stock deliver strong Q4 earningsMarket Activity Report & Growth Focused Investment Plans - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
San Gabriel Valley Tribune - FinancialContent
Amicus Therapeutics, Inc.Common Stock (NQ: FOLD - FinancialContent
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-EKSO, FOLD, CWAN, and JHG - The Malaysian Reserve
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.35%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):